Trial · NCT00680901
Results by group302
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 302
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival at the Time of Primary Analysis | CapeOx Plus Lapatinib | 12.2 | 95% Confidence Interval 10.6 to 14.2 | Months | |
| Overall Survival at the Time of Primary Analysis | CapeOx Plus Placebo | 10.5 | 95% Confidence Interval 9.0 to 11.3 | Months | |
| Overall Survival in All Randomized Participants at the Time of Primary Analysis | CapeOx Plus Lapatinib | 11.9 | 95% Confidence Interval 10.4 to 13.8 | Months | |
| Overall Survival in All Randomized Participants at the Time of Primary Analysis | CapeOx Plus Placebo | 10.4 | 95% Confidence Interval 9.1 to 11.3 | Months | |
| Overall Survival at the Time of Final Analysis | CapeOx Plus Lapatinib | 12.0 | 95% Confidence Interval 10.4 to 13.8 | Months | |
| Overall Survival at the Time of Final Analysis | CapeOx Plus Placebo | 10.4 | 95% Confidence Interval 9.0 to 11.3 | Months | |
| Progression Free Survival (PFS) | CapeOx Plus Lapatinib | 6.2 | 95% Confidence Interval 5.6 to 7.0 | Months | |
| Progression Free Survival (PFS) | CapeOx Plus Placebo | 5.4 | 95% Confidence Interval 4.4 to 5.7 | Months | |
| Percentage of Participants With a Confirmed Complete Response (CR) or a Partial Response (PR) | CapeOx Plus Lapatinib | 131 | Participants | ||
| Percentage of Participants With a Confirmed Complete Response (CR) or a Partial Response (PR) | CapeOx Plus Placebo | 94 | Participants | ||
| Percentage of Participants With Clinical Benefit (CB) | CapeOx Plus Lapatinib | 199 | Participants | ||
| Percentage of Participants With Clinical Benefit (CB) | CapeOx Plus Placebo | 188 | Participants | ||
| Time to Response (TTR) | CapeOx Plus Lapatinib | 1.4 | 95% Confidence Interval 1.4 to 1.5 | Months | |
| Time to Response (TTR) | CapeOx Plus Placebo | 1.4 | 95% Confidence Interval 1.4 to 1.6 | Months | |
| Duration of Response (DOR) | CapeOx Plus Lapatinib | 7.3 | 95% Confidence Interval 6.4 to 8.5 | Months | |
| Duration of Response (DOR) | CapeOx Plus Placebo | 5.6 | 95% Confidence Interval 4.6 to 6.0 | Months | |
| Percentage of Participants With Any On-therapy Adverse Event (AE) and Serious Adverse Event (SAE) | CapeOx Plus Lapatinib | On-Therapy Adverse Events (Any AE regardless of seriousness) | 255 | Participants | |
| Percentage of Participants With Any On-therapy Adverse Event (AE) and Serious Adverse Event (SAE) | CapeOx Plus Placebo | On-Therapy Adverse Events (Any AE regardless of seriousness) | 237 | Participants | |
| Percentage of Participants With Any On-therapy Adverse Event (AE) and Serious Adverse Event (SAE) | CapeOx Plus Lapatinib | On-Therapy Serious Adverse Events | 73 | Participants | |
| Percentage of Participants With Any On-therapy Adverse Event (AE) and Serious Adverse Event (SAE) | CapeOx Plus Placebo | On-Therapy Serious Adverse Events | 54 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00680901/results